Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UR 1505

Drug Profile

UR 1505

Alternative Names: UR-1505

Latest Information Update: 18 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Uriach
  • Developer Palau Pharma
  • Class Anti-inflammatories; Antipsoriatics; Salicylates; Small molecules
  • Mechanism of Action Immunomodulators; Lymphocyte inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atopic dermatitis; Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 18 Jan 2018 Discontinued - Phase-II for Atopic dermatitis in France (Topical), due to lack of efficacy
  • 24 Jul 2007 Discontinued - Preclinical for Inflammatory bowel disease in Spain (PO)
  • 24 Jul 2007 Discontinued - Preclinical for Psoriasis in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top